199 related articles for article (PubMed ID: 27190350)
1. Erythropoiesis-stimulating agent dosing, haemoglobin and ferritin levels in UK haemodialysis patients 2005-13.
Birnie K; Caskey F; Ben-Shlomo Y; Sterne JA; Gilg J; Nitsch D; Tomson C
Nephrol Dial Transplant; 2017 Apr; 32(4):692-698. PubMed ID: 27190350
[TBL] [Abstract][Full Text] [Related]
2. UK Renal Registry 16th annual report: chapter 10 haemoglobin, ferritin and erythropoietin amongst UK adult dialysis patients in 2012: national and centre-specific analyses.
Rao A; Gilg J; Williams A
Nephron Clin Pract; 2013; 125(1-4):183-208. PubMed ID: 24662174
[TBL] [Abstract][Full Text] [Related]
3. Effects of proactive iron and erythropoiesis-stimulating agent protocol implementation on achieving clinical guideline targets for anaemia in a satellite haemodialysis patient cohort.
Yong K; Kairaitis L
Nephrology (Carlton); 2010 Apr; 15(3):288-93. PubMed ID: 20470296
[TBL] [Abstract][Full Text] [Related]
4. Chapter 8 Haemoglobin, ferritin and erythropoietin amongst UK adult dialysis patients in 2010: national and centre-specific analyses.
Webb L; Gilg J; Wilkie M
Nephron Clin Pract; 2012; 120 Suppl 1():c145-74. PubMed ID: 22964566
[TBL] [Abstract][Full Text] [Related]
5. The Impact of Lowering Haemoglobin Targets on Patterns of Erythropoiesis-Stimulating Agent Use in Patients on Haemodialysis.
Hazara AM; Owen SJ; Bhandari S
Blood Purif; 2016; 41(4):287-92. PubMed ID: 26820617
[TBL] [Abstract][Full Text] [Related]
6. UK Renal Registry 11th Annual Report (December 2008): Chapter 9 Haemoglobin, ferritin and erythropoietin amongst patients receiving dialysis in the UK in 2007: national and centre-specific analyses.
Richardson D; Ford D; Gilg J; Williams AJ
Nephron Clin Pract; 2009; 111 Suppl 1():c149-83. PubMed ID: 19542697
[TBL] [Abstract][Full Text] [Related]
7. Anemia management trends in hospital-based dialysis centers (HBDCs), 2010 to 2013.
Coritsidis GN; Maglinte GA; Acharya A; Saxena A; Chang CL; Hill J; Gitlin M; Lafayette RA
Clin Ther; 2014 Mar; 36(3):408-18. PubMed ID: 24582713
[TBL] [Abstract][Full Text] [Related]
8. Understanding the Recent Increase in Ferritin Levels in United States Dialysis Patients: Potential Impact of Changes in Intravenous Iron and Erythropoiesis-Stimulating Agent Dosing.
Karaboyas A; Zee J; Morgenstern H; Nolen JG; Hakim R; Kalantar-Zadeh K; Zager P; Pisoni RL; Port FK; Robinson BM
Clin J Am Soc Nephrol; 2015 Oct; 10(10):1814-21. PubMed ID: 26286925
[TBL] [Abstract][Full Text] [Related]
9. 2008 Japanese Society for Dialysis Therapy: guidelines for renal anemia in chronic kidney disease.
Tsubakihara Y; Nishi S; Akiba T; Hirakata H; Iseki K; Kubota M; Kuriyama S; Komatsu Y; Suzuki M; Nakai S; Hattori M; Babazono T; Hiramatsu M; Yamamoto H; Bessho M; Akizawa T
Ther Apher Dial; 2010 Jun; 14(3):240-75. PubMed ID: 20609178
[TBL] [Abstract][Full Text] [Related]
10. Predictors of hyporesponsiveness to erythropoiesis-stimulating agents in hemodialysis patients.
Kalantar-Zadeh K; Lee GH; Miller JE; Streja E; Jing J; Robertson JA; Kovesdy CP
Am J Kidney Dis; 2009 May; 53(5):823-34. PubMed ID: 19339087
[TBL] [Abstract][Full Text] [Related]
11. UK Renal Registry 15th annual report: Chapter 6 haemoglobin, ferritin and erythropoietin amongst UK adult dialysis patients in 2011: national and centre-specific analyses.
Rao A; Gilg J; Williams A
Nephron Clin Pract; 2013; 123 Suppl 1():125-50. PubMed ID: 23774489
[TBL] [Abstract][Full Text] [Related]
12. UK Renal Registry 13th Annual Report (December 2010): Chapter 9: haemoglobin, ferritin and erythropoietin amongst UK adult dialysis patients in 2009: national and centre-specific analyses.
Gilg J; Webb L; Feest T; Fogarty D
Nephron Clin Pract; 2011; 119 Suppl 2():c149-77. PubMed ID: 21894032
[TBL] [Abstract][Full Text] [Related]
13. [Opatija study: observation of hemodialysis patients and titration of CERA dose just switched from another erythropoiesis stimulating agent].
Jelić I; Lovcić V; Kurtović I; Josipović M; Havranek Z; Kostić L; Racki S
Acta Med Croatica; 2012 Jul; 66(3):157-64. PubMed ID: 23441529
[TBL] [Abstract][Full Text] [Related]
14. Treatment of renal anaemia with erythropoiesis-stimulating agents in predialysis chronic kidney disease patients: Haemoglobin profile during the 6 months before initiation of dialysis.
Kawahara K; Minakuchi J; Yokota N; Suekane H; Tsuchida K; Kawashima S
Nephrology (Carlton); 2015 Dec; 20 Suppl 4():29-32. PubMed ID: 26456375
[TBL] [Abstract][Full Text] [Related]
15. Testosterone deficiency is a cause of anaemia and reduced responsiveness to erythropoiesis-stimulating agents in men with chronic kidney disease.
Carrero JJ; Bárány P; Yilmaz MI; Qureshi AR; Sonmez A; Heimbürger O; Ozgurtas T; Yenicesu M; Lindholm B; Stenvinkel P
Nephrol Dial Transplant; 2012 Feb; 27(2):709-15. PubMed ID: 21617198
[TBL] [Abstract][Full Text] [Related]
16. Trends in the treatment of chronic kidney disease-associated anaemia in a cohort of haemodialysis patients: the Irish experience.
Gardiner R; Roshan D; Brennan A; Connolly D; Murray S; Reddan D
Ir J Med Sci; 2019 Feb; 188(1):223-230. PubMed ID: 29704093
[TBL] [Abstract][Full Text] [Related]
17. [Effects of dose of erythropoiesis stimulating agents on cardiovascular outcomes, quality of life and costs of haemodialysis. the clinical evaluation of the DOSe of erythropoietins (C.E. DOSE) Trial].
Saglimbene V; D'Alonzo D; Ruospo M; Vecchio M; Natale P; Gargano L; Nicolucci A; Pellegrini F; Craig JC; Triolo G; Procaccini DA; Santoro A; Di Giulio S; La Rosa S; Murgo A; Di Toro Mammarella R; Sambati M; D'Ambrosio N; Greco V; Giannoccaro G; Flammini A; Boccia E; Montalto G; Pagano S; Amarù S; Fici M; Lumaga GB; Mancini E; Veronesi M; Patregnani L; Querques M; Schiavone P; Chimienti S; Palumbo R; Di Franco D; Della Volpe M; Gori E; Salomone M; Iacono A; Moscoloni M; Treglia A; Casu D; Piras AM; Di Silva A; Mandreoli M; Lopez A; Quarello F; Catizone L; Russo G; Forcellini S; Maccarone M; Catucci G; Di Paolo B; Stingone A; D'Angelo B; Guastoni C; Pasquali S; Minoretti C; Bellasi A; Boscutti G; Martone M; David S; Schito F; Urban L; Di Iorio B; Caruso F; Mazzoni A; Musacchio R; Andreoli D; Cossu M; Li Cavoli G; Cornacchiari M; Granata A; Clementi A; Giordano R; Guastoni C; Barzaghi W; Valentini M; Hegbrant J; Tognoni G; Strippoli GF
G Ital Nefrol; 2013; 30(2):. PubMed ID: 23832463
[TBL] [Abstract][Full Text] [Related]
18. Frequency of administration of erythropoiesis-stimulating agents for the anaemia of end-stage kidney disease in dialysis patients.
Hahn D; Cody JD; Hodson EM
Cochrane Database Syst Rev; 2014 May; 2014(5):CD003895. PubMed ID: 24872328
[TBL] [Abstract][Full Text] [Related]
19. Inflammation, high ferritin, and erythropoietin resistance in indigenous maintenance hemodialysis patients from the Top End of Northern Australia.
Majoni SW; Ellis JA; Hall H; Abeyaratne A; Lawton PD
Hemodial Int; 2014 Oct; 18(4):740-50. PubMed ID: 24766376
[TBL] [Abstract][Full Text] [Related]
20. Relationship between responsiveness to erythropoiesis-stimulating agent and long-term outcomes in chronic hemodialysis patients: a single-center cohort study.
Ogawa T; Shimizu H; Kyono A; Sato M; Yamashita T; Otsuka K; Nitta K
Int Urol Nephrol; 2014 Jan; 46(1):151-9. PubMed ID: 23807369
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
